Hydroxyzine Use in Anorexia Nervosa with MDD and Anxiety: High-Risk Medication Requiring Cardiac Monitoring
Hydroxyzine should be used with extreme caution—or avoided entirely—in patients with anorexia nervosa due to significant cardiac risks, particularly QT prolongation and Torsade de Pointes, which are compounded by the electrolyte abnormalities and cardiac complications inherent to anorexia nervosa.
Critical Cardiac Risks in This Population
The combination of hydroxyzine and anorexia nervosa creates a dangerous convergence of risk factors:
QT Prolongation Risk
Hydroxyzine carries an FDA warning for QT prolongation and Torsade de Pointes 1. The drug label explicitly states that hydroxyzine should be used with caution in patients with:
- Pre-existing heart disease
- Electrolyte imbalances
- Concomitant arrhythmogenic drug use
- Recent myocardial infarction
- Uncompensated heart failure
- Bradyarrhythmias 1
Anorexia Nervosa Creates Multiple Risk Factors
Patients with restrictive eating disorders like anorexia nervosa inherently possess several of these contraindicated conditions. The 2023 APA guidelines mandate ECG monitoring specifically for patients with restrictive eating disorders because of their elevated cardiac risk 2. These patients commonly present with:
- Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypophosphatemia)
- Bradycardia and orthostatic hypotension
- Prolonged QTc intervals at baseline
- Malnutrition-induced cardiac dysfunction
This creates a multiplicative risk when hydroxyzine is introduced, as the drug's QT-prolonging effects overlay an already compromised cardiac substrate 3.
Mandatory Pre-Treatment Evaluation
If hydroxyzine is being considered despite these risks, the following must be completed:
Required Baseline Assessment
Per APA guidelines for eating disorders 2:
- ECG to measure baseline QTc interval
- Complete metabolic panel including electrolytes (potassium, magnesium, calcium, phosphate)
- Complete blood count
- Vital signs including orthostatic measurements (pulse and blood pressure)
- Weight and BMI documentation
Absolute Contraindications
Do not prescribe hydroxyzine if:
- QTc >470 ms in women or >450 ms in men
- Uncorrected electrolyte abnormalities
- Concurrent use of other QT-prolonging medications (SSRIs like citalopram/fluoxetine, antipsychotics, certain antibiotics) 1
- Severe bradycardia (<50 bpm)
- Recent syncope or cardiac arrhythmias
Alternative Treatment Approaches
For Anxiety in Anorexia Nervosa
The 2023 APA guidelines do not recommend pharmacotherapy as first-line treatment for anorexia nervosa 2. Instead:
- Adults: Eating disorder-focused psychotherapy addressing anxiety as part of the disorder 2
- Adolescents/emerging adults: Family-based treatment 2
While hydroxyzine shows efficacy for generalized anxiety disorder 4, 5, 6, 7, these studies excluded medically compromised patients like those with anorexia nervosa.
For Comorbid Depression
If treating comorbid MDD after weight restoration, fluoxetine may be considered, particularly in patients with moderate-to-severe depression (BDI >20), as it has shown efficacy in reducing relapse in weight-restored AN patients with depression 8. However, note that fluoxetine itself carries QT prolongation risk and requires the same cardiac precautions 1.
Evidence for antidepressant efficacy in underweight patients with AN remains insufficient 9, and psychotherapy should remain the primary intervention.
If Hydroxyzine Must Be Used
Monitoring Protocol
- Correct all electrolyte abnormalities before initiating treatment
- Start at the lowest possible dose (the elderly dosing principle applies here due to medical fragility)
- Repeat ECG within 1 week of initiation and after any dose increase
- Weekly electrolyte monitoring initially, then at least monthly
- Monitor for CNS depression (drowsiness, sedation) which may impair nutritional rehabilitation 1
- Avoid alcohol and other CNS depressants 1
Drug Interactions
Exercise extreme caution with concomitant medications that prolong QT interval, including:
- SSRIs (citalopram, fluoxetine, escitalopram)
- Antipsychotics (quetiapine, olanzapine, ziprasidone)
- Antibiotics (azithromycin, fluoroquinolones)
- Antiemetics (ondansetron) 1
Additional Safety Concerns
Sedation and Weight Restoration
Hydroxyzine's sedating effects 1, 7 may interfere with the active participation required in eating disorder-focused psychotherapy and nutritional rehabilitation—the cornerstone treatments for anorexia nervosa 2.
Acute Generalized Exanthematous Pustulosis (AGEP)
Hydroxyzine rarely causes AGEP, a serious skin reaction. Discontinue immediately if rash develops 1.
Elderly Considerations
While this patient may not be elderly, the FDA label's warnings about starting low doses in elderly patients due to sedation and confusion 1 apply equally to medically compromised patients with anorexia nervosa.
Clinical Bottom Line
The risk-benefit ratio of hydroxyzine in anorexia nervosa is unfavorable. The cardiac risks are substantial and potentially life-threatening in a population already at elevated risk for sudden cardiac death. Psychotherapy remains the evidence-based first-line treatment 2. If pharmacological intervention for anxiety is absolutely necessary, consider alternatives without QT-prolonging effects after comprehensive cardiac evaluation and in consultation with cardiology.